rTMS for Postoperative Brain Tumor Patients
22–65
1 site in NY
About this study
This study is focused on people with brain tumors. The primary outcome being measured is Number of adverse events and serious adverse events experienced following transcranial magnetic stimulation sessions.
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of adverse events and serious adverse events experienced following transcranial magnetic stimulation sessions
Secondary: Motor recovery as evaluated by change from baseline in The Box and Block Test (BBT), Motor recovery as evaluated by change from baseline in the 10-Meter Walk Test (10MWT), Motor recovery as evaluated by change from baseline in the Barthel Index (BI), Motor recovery as evaluated by change from baseline in the Medical Research Council (MRC) Scale for Muscle Strength, Quality of life as evaluated by change from baseline in the EQ-5D-5L, Quality of life as evaluated by change from baseline in the Functional Assessment of Cancer Therapy - Brain (FACT-Br), Quality of life as evaluated by change from baseline in the QLQ-BN20
therapeutic
Neurology